Advanced glycation end products in patients with peripheral artery disease or abdominal aortic aneurysms
Completed
- Conditions
- Peripheral artery disease - atherosclerosis of the leg1000318410003216
- Registration Number
- NL-OMON45188
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 180
Inclusion Criteria
Age above 18 years old.
Written informed consent for study participation.
Proven PAD or AAA
PAD: patients planned for a bypass surgery or endarterectomy of the lower arteries, and/or:
AAA: patients planned for an open repair of the aneurysm.
Exclusion Criteria
Patients not able or willing to sign informed consent.
rheumatoid arthritis, systemic lupus erythematosus, Giant Cell Arteritis, retroperitoneal fibrosis, Takayasu arteritis or any other systemic inflammatory disorder.
Patients with Ehlers-Danlos syndrom or Marfan syndrom
Patients with signs of an inflammatory or mycotic aneurysm (on computed tomographic angiography).
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary objective is to compare the amount, type and localisation of AGEs<br /><br>of the arterial wall of PAD, AAA and PAD+AAA between patients with and without<br /><br>diabetes mellitus.</p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary objectives are to explore the association between AGEs content of<br /><br>the arterial wall of PAD, AAA and PAD+AAA patients and (1) serum, urine and<br /><br>skin AGEs, (2) in vivo and in vitro mechanical properties of the arterial wall<br /><br>and (3) serum, urine and tissue markers of inflammation and oxidative stress.</p><br>